MedTech firm CergenX raises an extra €1.2m for its product that screens brain injury in babies 

The device is scheduled to undergo regulatory approval next year, followed by a release in 2025.

Jason Mowles, CEO, Professor Geraldine Boylan, CSO, and Sean Griffin, CTO of CergenX.

A Cork based company that created a product to screen newborns for brain injury, CergenX, has raised an additional €1.2m in funding.

The funding will be injected into further developing the Newborn Brain Screener and recruiting professionals working in AI, product management and software engineering.